钆塞酸增强MRI早期动脉相PSR鉴别HCC代谢优势
本回顾性研究纳入38例患者48个HCC病灶,评估钆塞酸增强MRI各时相信号比PSR能否区分双示踪PET/CT上的代谢优势类型。结果显示早期动脉相PSR的AUC最高,为0.99,PSR阈值95.2可有效区分乙酸优势与FDG优势病灶。
要点
- 早期动脉相PSR低于95.2提示乙酸优势型HCC可能性大
- 乙酸优势组早期动脉相PSR中位数为64.7,FDG优势组为113.9
- 肝胆期PSR在两组间无显著差异,不用于代谢优势判断
核心结论
- 钆塞酸增强MRI的PSR尤其在早期动脉相可区分乙酸优势型与FDG优势型HCC。
研究设计与样本
- 共48个HCC病灶,按示踪剂亲和力分为乙酸优势组28个病灶与FDG优势组20个病灶。
- MRI信号强度以百分比信号比PSR量化,定义为病灶旁正常肝实质信号强度与病灶信号强度之比。
- 通过ROC曲线下面积AUC确定最佳鉴别代谢优势的MRI时相。
关键影像表现/征象
- 乙酸优势组在早期动脉相、晚期动脉相及门静脉相PSR中位数均低于FDG优势组。
- 早期动脉相PSR中位数为64.7对113.9,P<0.001;晚期动脉相为103.8对135.4,P<0.001。
- 门静脉相PSR中位数为114.5对142.3,P=0.001;肝胆期PSR无显著差异,为171.6对161.9,P=0.390。
诊断标准与关键数值
- 早期动脉相PSR的AUC最高,为0.99,95%CI为0.96至1.00,P<0.001。
- 早期动脉相PSR阈值95.2可有效区分HCC代谢优势类型。
临床应用与阅片要点
- 阅片时可测量早期动脉相病灶与邻近正常肝实质信号强度比,PSR低于95.2提示乙酸优势型HCC倾向。
- 肝胆期PSR不能用于区分代谢优势类型,报告时不应以肝胆期信号评价HCC代谢表型。
局限性
- 本研究为回顾性探索性设计,样本量较小,共48个病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The metabolic predominance of hepatocellular carcinoma (HCC) on dual-tracer PET/CT with C-11 acetate and F-18 fluorodeoxyglucose (FDG) reflects tumor differentiation, but a practical MRI-based biomarker for predicting this phenotype remains needed. This study aimed to assess whether enhancement patterns on gadoxetic acid-enhanced liver MRI can differentiate the metabolic predominance of HCC.
MATERIALS AND METHODS: This exploratory retrospective study included patients with HCC who underwent both dual-tracer PET/CT and liver MRI between January 2015 and December 2021. HCC lesions were categorized as acetate- or FDG-dominant based on tracer avidity. Signal intensity (SI) in each MRI phase was quantified using the percentage signal ratio (PSR), defined as the ratio of SI in adjacent normal liver parenchyma to that in the lesion. The area under the receiver operating characteristic curve (AUC) was measured to determine the MRI phase that best distinguished the metabolic predominance of HCC lesions.
RESULTS: In 38 patients (mean age, 62.0±8.0 years) with 48 HCC lesions, median PSR values were lower in acetate-dominant group (28 lesions) than in FDG-dominant group (20 lesions) during the early arterial (64.7 vs. 113.9; P<0.001), late arterial (103.8 vs. 135.4; P<0.001), and portal venous (114.5 vs. 142.3; P = 0.001) phases, but not in the hepatobiliary phase (171.6 vs. 161.9; P = 0.390). The AUC was highest in the early arterial phase (0.99; 95% CI: 0.96, 1.00; P<0.001), where a PSR cutoff of 95.2 effectively distinguished the metabolic predominance of HCC.
CONCLUSION: PSR on liver MRI, especially in the early arterial phase, differentiates acetate- from FDG-dominant HCCs, indicating metabolic predominance.
引用
- Moon, Heo, Kang, et al. Gadoxetic Acid-Enhanced Liver MRI for Differentiating Metabolic Predominance in Hepatocellular Carcinoma on Dual-Tracer PET/CT. Acad Radiol. 2026. PMID: 41530026. doi:10.1016/j.acra.2025.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。